利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.014 秒)

    N-ETHYL-4-HYDROXYL-1-METHYL-5-(METHYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE
    1.
    发明申请
    N-ETHYL-4-HYDROXYL-1-METHYL-5-(METHYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE 有权
    N-乙基-4-羟基-1-甲基-5-（甲基（2,3,4,5,6-二羟甲基）氨基）-2-氧代-N-苯基-1,2-二氢喹啉-3-羧酰胺

    公开(公告)号：US20130345256A1

    公开(公告)日：2013-12-26

    申请号：US13888709

    申请日：2013-05-07

    申请人： Avital Laxer ,  Konstantin Ulanenko

    发明人： Avital Laxer ,  Konstantin Ulanenko

    IPC分类号： C07D215/56 ,  A61K31/4704

    CPC分类号： C07D215/56 ,  A61K31/4704 ,  A61K2300/00

    摘要： The subject invention provides pharmaceutical compositions containing laquinimod or a pharmaceutically acceptable salt thereof, an isolated compound of N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide or a salt thereof, compositions containing N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide and methods of preparing the same.

    摘要翻译： 本发明提供含有拉喹莫德或其药学上可接受的盐，N-乙基-4-羟基-1-甲基-5-（甲基（2,3,4,5,6-五羟基己基）氨基）的分离化合物的药物组合物， -2-氧代-N-苯基-1,2-二氢喹啉-3-甲酰胺或其盐包含N-乙基-4-羟基-1-甲基-5-（甲基（2,3,4,5， 6-五羟基己基）氨基）-2-氧代-N-苯基-1,2-二氢喹啉-3-甲酰胺及其制备方法。

    N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
    6.
    发明授权
    N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide 有权
    N-乙基-4-羟基-1-甲基-5-（甲基（2,3,4,5,6-五羟基己基）氨基）-2-氧-N-苯基-1,2-二氢喹啉-3-甲酰胺

    公开(公告)号：US08809537B2

    公开(公告)日：2014-08-19

    申请号：US13888709

    申请日：2013-05-07

    申请人： Avital Laxer ,  Konstantin Ulanenko

    发明人： Avital Laxer ,  Konstantin Ulanenko

    IPC分类号： A61K31/47 ,  C07D215/00

    CPC分类号： C07D215/56 ,  A61K31/4704 ,  A61K2300/00

    摘要： The subject invention provides pharmaceutical compositions containing laquinimod or a pharmaceutically acceptable salt thereof, an isolated compound of N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide or a salt thereof, compositions containing N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide and methods of preparing the same.

    摘要翻译： 本发明提供含有拉喹莫德或其药学上可接受的盐，N-乙基-4-羟基-1-甲基-5-（甲基（2,3,4,5,6-五羟基己基）氨基）的分离化合物的药物组合物， -2-氧代-N-苯基-1,2-二氢喹啉-3-甲酰胺或其盐包含N-乙基-4-羟基-1-甲基-5-（甲基（2,3,4,5， 6-五羟基己基）氨基）-2-氧代-N-苯基-1,2-二氢喹啉-3-甲酰胺及其制备方法。

    Preparation of warfarin sodium from warfarin sodium-2-propanol clathrate by solvent expulsion
    9.
    发明授权
    Preparation of warfarin sodium from warfarin sodium-2-propanol clathrate by solvent expulsion 有权
    通过溶剂驱除从华法林钠-2-丙醇包合物制备华法林钠

    公开(公告)号：US06610862B2

    公开(公告)日：2003-08-26

    申请号：US09794207

    申请日：2001-02-28

    申请人： Sorin Bercovici ,  Shimon Chernyak ,  Konstantin Ulanenko

    发明人： Sorin Bercovici ,  Shimon Chernyak ,  Konstantin Ulanenko

    IPC分类号： C07D31102

    CPC分类号： C07D311/46

    摘要： The present invention is a method for producing warfarin sodium from warfarin sodium 2-propanol clathrate by thermal, nondestructive solvent expulsion. The solvent expulsion is conducted under conditions of controlled heat transfer whereby the 2-propanol is expelled from the warfarin sodium 2-propanol clathrate without decomposition of warfarin sodium or the clathrate. Heating is conducted the clathrate at a temperature from about 100° C. to about 170° C. in an active oven under air or in an inert atmosphere and at partial pressures ranging from that of a relative vacuum to atmospheric pressure. The invention also relates to pure warfarin sodium prepared according to the method of the invention and pharmaceutical compositions containing warfarin sodium.

    摘要翻译： 本发明是通过热，非破坏性溶剂驱除从华法林钠2-丙醇包合物制备华法林钠的方法。 溶剂排出在受控热转移的条件下进行，由此2-氟丙醇从华法林钠2-丙醇包合物中排出而不分解华法林钠或包合物。 在活性烘箱中在空气或惰性气氛中并且在相对真空至大气压的分压下，在约100℃至约170℃的温度下进行加热。 本发明还涉及根据本发明的方法制备的纯华法林钠和含有华法林钠的药物组合物。